INTRODUCTION AND OBJECTIVES: Available recommendations for extended lymph node dissection [eLND] at radical prostatectomy [RP] do not consider patient age, but rely on cancer characteristics only. However, for patients with limited life-expectancy, eLND might be an overtreatment. We hypothesized that limited life-expectancy of older RP candidates might dilute any beneficial effect of eLND in terms of cancer staging and outcomes. Therefore, we aimed at assessing the differential effect of age on the risk of lymph node invasion [LNI] and mortality due to cause other than prostate cancer [OCM] in order to define an age limit above which eLND might be avoided.
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METHODS: We included 3,906 patients diagnosed with prostate cancer and treated with RP and an anatomically defined eLND at a single Institution. Logistic and Cox regression analyses were used to compute the risk of LNI at eLND and the risk of OCM 10 years after RP. Predictors of LNI were chosen in compliance with guidelines-recommended models and were PSA, primary and secondary biopsy Gleason score and clinical stage. Predictors of OCM were age at surgery, Charlson comorbidity index [CCI] and year of surgery. Locally weighted scatterplot smoothing method was used to graphically examine the differential effect of age on the risk of LNI and OCM.
RESULTS: Median age was 65 years. LNI rate was 12%. 10year OCM rate was 5%. PSA (odd ratio [OR] 1.06; p<0.001), primary (OR 5.32; p<0.001) and secondary (OR 2.27; p<0.001) biopsy Gleason score 4 as well as clinical stage cT2 (OR 2.4; p<0.001) and cT3 (OR 3.24; p<0.001) were associated with higher LNI risk. Age (hazard ratio [HR] 1.11; p<0.001) and CCI (HR 1.28; p¼0.03) were associated with higher OCM risk. Year of surgery (HR 0.92; p<0.001) was associated with lower OCM risk. For patients aged 75 or younger, the risk of LNI (8-11%) was higher than the risk of OCM (<1-10%; Figure 1 ). Conversely, for patients aged 76 or older the risk of LNI (11-17%) was equal or lower than the risk of OCM (11-26%).
CONCLUSIONS: For RP candidates older than 75 years, the risk of OCM equals or exceeds the risk of LNI. Such relatively high risk of OCM compared to the relatively low risk of LNI casts relevant doubts on any potential benefit related to eLND at RP. These findings argue against the routine use of eLND for older patients in clinical practice. Makoto Ohori*, Tatsuo Gondo, Yosuke Hirasawa, Takeshi Hashimoto, Yoshihiro Nakagami, Rie Inoue, Takashi Nagao, Tokyo, Japan INTRODUCTION AND OBJECTIVES: Because of the spread of saturation biopsy and MRI guided needle biopsy, we may often see a cancer in transition zone (TZ). To assess whether there is a difference in prognosis in TZ and peripheral zone (PZ) prostate cancer, we studied the patients with clinically localized prostate cancers who had RARP.
Source of
METHODS: We studied retrospectively the clinical and pathological features of 404 consecutive patients with prostate cancer treated with RARP by one surgeon at Tokyo Medical University. We categorized the patients into predominantly PZ cancer, TZ cancer and both TZPZ cancer based on the area of cancer on whole-mount step sections of RARP specimens. Biochemical recurrence (BCR) was evaluated using the Kaplan-Meier method. With a Cox hazard regression analysis, we identified significant preoperative factors that predict BCR, and based on these results, we developed a nomogram to predict the non-BCR at 5 years after RARP. A concordance index was used to assess the value of a nomogram, and a calibration plot was used to compare the predicted values to actual values.
RESULTS: PZ, TZ and both cancer was identified in 64%, 33% and 3% of the patients, respectively. Non-BCR rates at 2 and 5 year for patients with PZ were 88% and 78%, respectively, compared to 97% and 97% for patients with TZ cancer (p¼0.0072). Also, none of 10 patients with both cancer had a BCR. While the frequency of positive surgical margins was similar between PZ and TZ groups (28% for both), the patients with PZ were more likely to have seminal vesicle invasion compared to patients with TZ (10% vs. 1%, p¼0.001) and to have >¼4+3/4+4 Gleason score (52% vs.40%, p¼0.37). In fact, in the absence of seminal vesicle invasion and >¼4+3/4+4 Gleason score, non-BCR rate at 3 year was 95% for patients with PZ and 99% for patients with TZ (p¼0.40). A Cox hazard regression analysis showed that zonal distribution of cancer (p¼0.004) was significantly associated with BCR after controlled with PSA, pathological stage, Gleason score and surgical margins. Based on this analysis, the postoperative momogram to predict non-BCR was constructed with an excellent concordance index of 0.89. The calibration plots also appeared to be good.
CONCLUSIONS: We concluded that the prognosis of a patient with prostate cancer is significantly more dependent upon the features of cancer in the PZ than in the TZ. Assessment of zonal distribution of cancer is important to gauge prognosis. INTRODUCTION AND OBJECTIVES: Radical prostatectomy (RP) is a primary treatment option for men with intermediate risk (IR) prostate cancer (PCa). Though many will be effectively cured with local therapy alone, these men are by definition at higher risk of disease recurrence. In this study, we evaluated whether a genomic signature of metastasis risk (Decipher PCa classifier) could improve pre-operative staging for predicting lymph node invasion (LNI).
METHODS: We examined 263 NCCN intermediate men treated with RP and extended template pelvic lymph node dissection (ePLND) from 2007-2015 at MD Anderson Cancer Center, Houston, Texas.
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